Events

Apollo Therapeutics will be attending the 8th Annual RAS-Targeted Drug Development Summit in Boston, September 8-10. 

On September 9, our Chief Medical Officer, Sanjay Aggarwal, will be presenting a poster featuring preclinical data demonstrating that pharmacological inhibition of the SHOC2 complex with our novel inhibitor, APL-MD1, delivers monotherapy efficacy in RAS-driven tumors and synergistic activity in combination with RAS inhibitors. 

We look forward to engaging with colleagues advancing the next generation of therapies for RAS-driven cancers.